LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

HCA Healthcare to Present at March Healthcare Conferences

February 20, 2025 | Last Trade: US$403.08 1.89 -0.47

NASHVILLE, Tenn. / Feb 20, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present virtually at the following healthcare conferences:

March 4, 2025 at 1:50pm ET at TD Cowen’s 45th Annual Healthcare Conference.

March 11, 2025 at 1:30pm ET at Barclays’ 27th Annual Global Healthcare Conference.

March 19, 2025 at 2:15pm ET at KeyBanc’s 5th Annual Healthcare Forum.

March 20, 2025 at 10:00am ET at Oppenheimer’s 35th Annual Healthcare MedTech & Services Conference.

A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.

About HCA Healthcare

Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

Terns Pharmaceuticals

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page